Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Posted on by Pencis

Prof. Dr. Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Harbin Normal University | China

AUTHOR PROFILE

Scopus

🧑‍🏫 YINGXUE JIN – PROFESSIONAL PROFILE

🎓 EARLY ACADEMIC PURSUITS

Yingxue Jin embarked on his academic journey with a strong foundation in science, eventually earning a Doctor of Science degree from Pusan National University in Korea in 2003. His academic background laid the groundwork for his expertise in pharmaceutical engineering and drug design. During his doctoral studies, he specialized in small molecule cyclic peptide drugs and nanodrug delivery systems, establishing a solid base for his future research contributions.

💼 PROFESSIONAL ENDEAVORS

Yingxue Jin has accumulated over three decades of experience in academia and research, holding key positions in prestigious institutions and companies:

  • Professor at Jiamusi University (1990 – 1999): Contributed to teaching and research in pharmaceutical sciences.

  • Senior Researcher at Korea Ilshin Chemical Company (2003 – 2004): Engaged in advanced chemical research, expanding his expertise in molecular synthesis.

  • Postdoctoral Researcher at Taiwan University, China (2005 – 2006): Conducted postdoctoral studies, refining his knowledge in pharmaceutical engineering and drug delivery mechanisms.

  • Professor at Harbin Normal University, China (2006 – Present):

    • Serving as Head of the Department of Pharmaceutical Engineering.

    • Director of Heilongjiang Chemical Society of China, promoting chemical science advancements.

    • Awarded the honorary title of “Famous Teacher” at Harbin Normal University, recognizing his excellence in education and mentorship.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACO-ONCOLOGY

Yingxue Jin’s primary research interests revolve around:

  • Design and Synthesis of Small Molecule Cyclic Peptide Drugs: Developing novel peptide-based therapeutic agents for various diseases, including cancer.

  • Anti-Tumor Nanodrug Delivery Systems: Innovating targeted drug delivery methods to enhance the efficacy and precision of cancer treatments.

  • Project Leadership:

    • Presided over two projects funded by the Natural Science Foundation of China (NSFC).

    • Led the implementation of one key project and two general projects under the Natural Science Foundation of Heilongjiang Province, China.

    • Supervised three natural science projects for the Heilongjiang Provincial Education Department, China.

🏅 IMPACT AND INFLUENCE

Yingxue Jin’s impactful contributions have been widely recognized through multiple awards and honors:

  • Natural Science and Technology Award of Heilongjiang Province: Acknowledging his significant scientific achievements.

  • Science and Technology Award of Heilongjiang Provincial Education Department: Recognizing his contributions to technological advancements in education.

  • Teaching Quality Award at Harbin Normal University (Multiple Occasions): Honoring his dedication to educational excellence and mentorship.

📚 ACADEMIC CITATIONS

Throughout his career, Yingxue Jin’s research has been widely cited in scientific publications, reflecting the influence and relevance of his work in the fields of pharmaceutical sciences, chemical engineering, and nanomedicine. His contributions have been referenced in numerous peer-reviewed journals, further establishing his reputation as a leading researcher in his field.

🌍 LEGACY AND FUTURE CONTRIBUTIONS

Yingxue Jin’s legacy is marked by his dedication to scientific innovation, educational mentorship, and pharmaceutical advancements. Moving forward, he aims to:

  • Expand his research in nanodrug delivery systems, focusing on precision medicine for oncology applications.

  • Foster collaborations with international research institutions to drive cross-disciplinary advancements.

  • Continue mentoring the next generation of scientists, contributing to the development of future leaders in pharmaceutical sciences.

🛡️ KEY ACHIEVEMENTS AND RECOGNITION

  • Honorary Title: Famous Teacher of Harbin Normal University.

  • Leadership Roles: Head of the Department of Pharmaceutical Engineering and Director of Heilongjiang Chemical Society of China.

  • Award-Winning Scientist: Recipient of multiple science and technology awards.

  • Renowned Educator: Consistently recognized for outstanding teaching quality.

🚀 CONCLUSION

Yingxue Jin’s extensive experience, innovative research, and dedication to scientific excellence and education have positioned him as a distinguished figure in the field of pharmaceutical sciences. His continued contributions to nanodrug delivery systems and cyclic peptide drug design are paving the way for groundbreaking advancements in cancer treatment and precision medicine.

 

📊🔬NOTABLE PUBLICATION:

  • 1️⃣ Exploring the Potential of Cyclic Peptidyl Antitumor Agents Derived from Natural Macrocyclic Peptide Phakellistatin 13

    Authors: Tong T. Li, Shitian S. Jiang, Tingting T. Li, Yingxue Y. Jin, Zhiqiang Z. Wang
    Journal: Journal of Medicinal Chemistry
    Year: 2024

    2️⃣ Enhanced Catalytic Activity of Fe3O4-Carbon Dots Complex in the Fenton Reaction for Enhanced Immunotherapeutic and Oxygenation Effects

    Authors: Guanghao G. Li, Yujun Y. Bao, Hui H. Zhang, Zhiqiang Z. Wang, Yingxue Y. Jin
    Journal: Journal of Colloid and Interface Science
    Year: 2024

    3️⃣ A Novel Nanomedicine Integrating Ferroptosis and Photothermal Therapy, Well-Suitable for PD-L1-Mediated Immune Checkpoint Blockade

    Authors: Yujun Y. Bao, Guanghao G. Li, Siqi S. Li, Changhong C. Guo, Yingxue Y. Jin
    Journal: Materials Today Bio
    Year: 2024

    4️⃣ Targeted Delivery of Rhein via Hyaluronic Acid Modified Liposomes for Suppression of Growth and Metastasis of Breast Cancer

    Authors: Jingchun J. Wang, Dijing D. Fan, Defu D. Cai, Yingxue Y. Jin
    Journal: International Journal of Biological Macromolecules
    Year: 2024

    5️⃣ DFT-Aided Stereo-Structural and Electronic Structure Studies of Poly-Hydroxyl Substituted Chlorophyllous Molecules

    Authors: Xiong X. Zhang, Tingting T. Li, Qi Q. Wang, Wen W. Fang, Zhiqiang Z. Wang
    Journal: Computational and Theoretical Chemistry
    Year: 2024

Ms. Xiaorong Zhu | Multiple Myeloma | Best Researcher Award

Posted on by Pencis

Ms. Xiaorong Zhu | Multiple Myeloma | Best Researcher Award

Baotou Medical College of Inner Mongolia University of Science and Technology | China

Author Profile

ORCID Id

👩‍⚕️💉Xiaorong Zhu: Aspiring Internal Medicine Physician 

🎓 Education Experience

  • 🎓2016.09-2021.07: Bachelor’s in Clinical Medicine
    Baotou Medical College, Inner Mongolia University of Science and Technology
  • 🏥2021.09-2024.07: Master’s in Internal Medicine
    Baotou Medical College, Inner Mongolia University of Science and Technology

🩺 Internship Experience

  • 🏨2019.08-2021.07: Baotou City Central Hospital (Fieldwork)
    • 🏥Completed rotations in Internal Medicine, Surgery, Obstetrics & Gynecology, and Emergency Department.
    • ⚕️Gained practical experience diagnosing and treating common diseases.
  • 🩺2021.09-2024.07: Baotou City Central Hospital (Resident Training)
    • 💉Participated in over 100 clinical cases, working closely with senior physicians.
    • 🔬Skilled in bone marrow punctures, biopsies, and other key clinical procedures.

🎯 School Experience

  • 🎓2016.09-2021.07: Undersecretary, Student Union of Central Clinical Medical School
    • 📚Organized medical seminars, attracting over 200 participants.
    • 🩺👩‍⚕️Coordinated clinical skills workshops, helping 100 students improve their skills.
    • 🤝💡Led volunteer projects, involving 300 student volunteers.

🏆 Relevant Skills

  • 📜Certified in Standardized Resident Training (Internal Medicine)
  • 📖Fluent in English (CET-4), with strong reading and writing abilities
  • ✍️Holder of Internal Medicine Qualification & Registration Certificates

🌟 Xiaorong Zhu is a dedicated physician in training, passionate about advancing patient care and mastering clinical skills in Internal Medicine. 🌿👩‍⚕️

✨Conclusion🎯

👩‍⚕️In summary, Xiaorong Zhu is a driven and skilled emerging physician with a strong foundation in Clinical Medicine and Internal Medicine. With hands-on experience in diverse medical fields, including rotations and resident training at Baotou City Central Hospital, she has developed expertise in clinical diagnosis and advanced procedures like bone marrow biopsies. Her leadership roles in academic and volunteer initiatives further demonstrate her dedication to the medical field and commitment to improving patient care. As Xiaorong continues her journey, she is poised to make significant contributions to the healthcare community. 🌟💉.

 

📊🔬NOTABLE PUBLICATION:

 

    • Function of NLRP3 inflammasome activation in multiple myeloma
      • Authors: Xiaorong Zhu, Jie Yu, Mingqiang Hua, Ning Xu, Lianjuan Wang, Lingkai Chen, Yanhong Jia, Xueyun Zhao
        Journal: Hematology
        Year: 2024

Mrs. Jelena Kovacic | New Drug Development | Best Researcher Award

Posted on by Pencis

Mrs. Jelena Kovacic | New Drug Development | Best Researcher Award

Faculty of Pharmacy and Biochemistry University of Zagreb | Croatia

Author Profile

Scopus

ORCID ID

Google Scholar

🎓EARLY ACADEMIC PURSUITS 

Jelena Kovačić embarked on her academic journey with a Master of Science in Applied Chemistry from the Faculty of Chemical Engineering and Technology in Zagreb, completed in 2021. Her master’s thesis focused on the monitoring of degradation of selected active substances, laying a solid foundation for her research career.

🔬PROFESSIONAL ENDEAVORS 

Jelena is currently a Ph.D. researcher at the Faculty of Pharmacy and Biochemistry, University of Zagreb. Her work primarily involves developing advanced analytical methods for drugs and biologically active substances, specifically targeting treatments for inflammatory bowel disease. Her role also includes involvement in stability-indicative methods, compatibility studies, and therapeutic drug monitoring.

🧪CONTRIBUTIONS AND RESEARCH FOCUS ON NEW DRUG DEVELOPMENT

Jelena’s research contributions are centered around preformulation studies, including forced degradation studies and compatibility assessments. She is also engaged in bioanalytical research, focusing on therapeutic drug monitoring and microextraction techniques. Her work involves advanced analytical techniques such as liquid chromatography (LC), mass spectrometry (MS), and chemometrics.

🌟IMPACT AND INFLUENCE 

Through her active participation in international symposia and congresses, Jelena has contributed to the broader scientific community’s understanding of analytical methods and bioanalytical techniques. Her research aims to enhance the efficacy and safety of drug treatments, particularly in the context of inflammatory bowel diseases.

📚ACADEMIC CITATIONS 

Jelena has established a growing presence in the academic community with her research contributions and presentations at various international platforms. Her work is expected to garner more citations as she progresses in her doctoral studies and publishes her findings.

🔮LEGACY AND FUTURE CONTRIBUTIONS 

Jelena Kovačić’s future contributions are anticipated to make a significant impact on the field of pharmaceutical sciences. With her expertise in developing advanced analytical methods and her dedication to research in drug treatments, she is poised to advance the understanding and application of these methods in clinical settings, thereby shaping future research and development in the field.

🎯Conclusion

Jelena Kovačić is an emerging researcher with a strong foundation in applied chemistry and a promising trajectory in pharmaceutical sciences. Her academic pursuits and professional experiences reflect a deep commitment to advancing analytical methods and bioanalytical techniques, particularly in the treatment of inflammatory bowel disease. Through her work, she contributes valuable insights into drug development and stability, enhancing the field’s overall knowledge and application. Her active participation in international forums and her ongoing research efforts position her as a future leader in pharmaceutical research, with the potential to significantly influence drug treatment methodologies and improve patient outcomes. As she continues to develop her expertise, Jelena is set to leave a lasting impact on the scientific community

📊🔬NOTABLE PUBLICATION:

 

  • Polyphenol content and antioxidant activity of phytoestrogen containing food and dietary supplements: DPPH free radical scavenging activity by HPLC
    • Authors: Klarić, D.A., Mornar, A., Kovačić, J., Brletić, I., Klarić, I.
    • Journal: Acta Pharmaceutica
    • Year: 2022

 

  • Accessing Lipophilicity and Biomimetic Chromatography Profile of Biologically Active Ingredients of Botanicals Used in the Treatment of Inflammatory Bowel Disease
    • Authors: Jeličić, M.-L., Amidžić Klarić, D., Kovačić, J., Verbanac, D., Mornar, A.
    • Journal: Pharmaceuticals
    • Year: 2022

 

  • Green Solid-Phase (Micro)Extraction of Andrographolides from Human Plasma Samples Followed by UHPLC-DAD-QqQ-MS/MS Analysis
    • Authors: Kovačić, J., Jeličić, M.-L., Amidžić Klarić, D., Mornar, A.
    • Journal: Separations
    • Year: 2023

 

  • Antioxidant Activity of Pharmaceuticals: Predictive QSAR Modeling for Potential Therapeutic Strategy
    • Authors: Jeličić, M.-L., Kovačić, J., Cvetnić, M., Mornar, A., Klarić, D.A.
    • Journal: Pharmaceuticals
    • Year: 2022

 

  • Size exclusion chromatography as green support for forced degradation study of adalimumab
    • Authors: Kovačić, J., Klarić, D.A., Turk, N., Mornar, A.
    • Journal: Acta Pharmaceutica
    • Year: 2023

Dr. Lei Xia | Theranostics | Best Researcher Award

Posted on by Pencis

Dr. Lei Xia | Theranostics | Best Researcher Award

Peking University Cancer Hospital |  China

Author Profile

Scopus

Orcid Id

Dr. Xia Lei, PhD 🧬

Affiliation:
Department of Nuclear Medicine, Peking University Cancer Hospital
Physician, Associate Researcher

Contact Information:
📞 Phone: 18811177191
✉️ Email: xialei9012288@126.com

Biography:

Dr. Xia Lei, PhD, currently serves as a physician and associate researcher in the Department of Nuclear Medicine at Peking University Cancer Hospital. Dr. Lei graduated from the Medical School of Peking University in 2020. His expertise and research interests lie in the innovative field of nuclear medicine, particularly focusing on the development and clinical application of radiopharmaceutical probes for tumor targeting.

His primary research areas include:

  1. Construction of Tumor-Targeted Multimodal Imaging Molecular Probes 🩻
    • Dr. Lei is dedicated to creating advanced imaging probes that can target tumors with high precision, enhancing the accuracy of tumor detection and diagnosis.
  2. Development and Preliminary Application of Novel Integrated Diagnostic and Therapeutic Probes 🧫
    • He is pioneering the integration of diagnostic and therapeutic functions into single probes, aiming to streamline and improve the effectiveness of cancer treatment.
  3. Preparation and Clinical Translation of Tumor-Targeted Radiopharmaceutical Probes 🧪
    • Dr. Lei’s work involves preparing radiopharmaceuticals that specifically target tumors and translating these innovations from the lab to clinical settings to benefit patients.

Principal Investigator in Projects:

Dr. Lei has been the principal investigator for several prestigious projects, showcasing his leadership in research and innovation:

  1. National Natural Science Foundation of China, Young Scientists Fund (NO.82202201) 🌟
    • RMB 300,000 (January 2023 – December 2025)
  2. Young Talents Support Plan by the China Association for Science and Technology (NO. YESS20220230) 🌟
    • RMB 600,000 (January 2023 – December 2025)
  3. Beijing Natural Science Foundation, General Program (NO.7242266) 🌟
    • RMB 200,000 (January 2024 – December 2026)
  4. Peking University Cancer Hospital Science Innovation and Translation Fund 🌟
    • RMB 140,000 (January 2024 – December 2024)
  5. Medical School of Peking University, Young Scientists Innovation Fund 🌟
    • RMB 40,000
  6. Internal Fund of Peking University Cancer Hospital 🌟
    • RMB 80,000
  7. Peking University Cancer Hospital Science Innovation Nurturing Fund 🌟
    • RMB 100,000

Dr. Lei’s contributions to the field of nuclear medicine are instrumental in advancing the understanding and treatment of cancer, reflecting his commitment to medical innovation and patient care.

 

📊🔬Notable Publication:

 

 

 

 

Drug Design and Clinical Trials

Posted on by Pencis

Drug Design and Clinical Trials

 

Introduction: Drug Design and Clinical Trials

The field of drug design and clinical trials represents a crucial bridge between scientific innovation and the improvement of human health. It encompasses the intricate processes involved in developing new pharmaceutical agents, assessing their safety and efficacy, and ultimately bringing them to the patients who need them. This dynamic and collaborative field plays a pivotal role in advancing medical treatments and therapeutics for a wide range of diseases and conditions.

Subtopics:

Rational Drug Design: Rational drug design involves the targeted creation of new drugs based on a deep understanding of the biological mechanisms underlying diseases. This subtopic explores the principles and techniques used in designing drugs with enhanced specificity and effectiveness.

Preclinical Testing: Before advancing to human trials, potential drug candidates undergo rigorous preclinical testing. This subtopic discusses the various stages of preclinical testing, including in vitro and animal studies, to evaluate safety and efficacy.

Clinical Trial Phases: Clinical trials are divided into phases, each serving a distinct purpose. This subtopic outlines the different phases (Phase I, II, III, and IV) of clinical trials, highlighting their objectives and the types of participants involved.

Patient Recruitment and Informed Consent: The recruitment of participants and obtaining informed consent are critical ethical aspects of clinical trials. This subtopic explores the importance of ethical considerations, participant rights, and the informed consent process in clinical research.

Data Analysis and Regulatory Approval: After the completion of clinical trials, data analysis and regulatory approval processes determine the fate of a drug candidate. This subtopic delves into the statistical methodologies used to analyze trial data and the regulatory agencies responsible for approving new drugs for market release.